Analyst Group: Equity Research Report on Genetic Analysis - Sustained Long-Term Growth Outlook Supported by Platform Strategy
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for diagnostic analysis of microbiomes — the collection of microorganisms in the body that support digestion, immunity, and overall health. The human microbiome market is growing fast, as its importance for health has been increasingly recognized, yet the field has so far lacked standardization. The GA-map® platform aims to standardize microbiome diagnostics, which is expected to generate high long-term sales growth with a CAGR of 37% from 2025-2028. With an applied EV/S multiple of 1.9x on 2027’s estimated sales of NOK 31.5m and a discount rate of 11.8%, a potential present value per share of NOK 0.95 (1.05) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.